Q4 2017 13F Holders as of 12/31/2017
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
20.8M
-
Number of holders
-
258
-
Total 13F shares, excl. options
-
154M
-
Shares change
-
+1.17M
-
Total reported value, excl. options
-
$9.21B
-
Value change
-
+$141M
-
Put/Call ratio
-
0.15
-
Number of buys
-
137
-
Number of sells
-
-112
-
Price
-
$59.72
Significant Holders of Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NKTR) as of Q4 2017
307 filings reported holding NKTR - Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2017.
Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NKTR) has 258 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 154M shares
.
Largest 10 shareholders include PRIMECAP MANAGEMENT CO/CA/ (22.4M shares), BlackRock Inc. (21.4M shares), Vanguard Group Inc (14.8M shares), OppenheimerFunds, Inc. (14.6M shares), FMR LLC (11.2M shares), STATE STREET CORP (3.98M shares), PointState Capital LP (3.93M shares), JANUS HENDERSON GROUP PLC (3.81M shares), Camber Capital Management LLC (3.35M shares), and NORGES BANK (2.42M shares).
This table shows the top 258 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.